Version history

{
  "session_id": "sess_sda-2026-04-01-gap-9137255b_20260412-083525",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Mechanistically Novel Hypotheses: Protein Aggregation Cross-Seeding in Neurodegeneration\n\n---\n\n## Hypothesis 1: Galectin-3 as a Universal Sensor-Dependent Cross-Seeding Platform at Damaged Endo/Lysosomal Membranes\n\n### Mechanism\nGalectin-3 (LGALS3) functions as a \"damage scaffold\" that simultaneously recruits multiple aggregation-prone proteins (Aβ42, α-synuclein, TDP-43) to ruptured endolysosomal membranes, creating a localized high-concentration environment that favors cross-nucleation. The galectin carbohydrate recognition domain recognizes exposed glycans on damaged organelle membranes, while its N-terminal intrinsically disordered region provides a phase-separated condensation surface amenable to amyloid nucleation. This sensor-dependent mechanism differs fundamentally from template-based seeding—it requires membrane damage as a prerequisite, explaining why traumatic brain injury and viral infections increase cross-disease risk.\n\n### Key Evidence\nGalectin-3 localizes to lysosomal damage sites in neurodegeneration models (Papadopoulos et al., 2017; PMID: **28781166**). Galectin-3 deficiency in 5xFAD mice reduces amyloid plaque pathology through unclear mechanisms (Nomura et al., 2020; PMID: **32209429**).\n\n### Testable Prediction\nDelete LGALS3 in P301S;APP/PS1 mice (cross-disease tau/Aβ model). If galectin-3 drives cross-seeding, double-knockout mice should show reduced tau aggregation acceleration by Aβ plaques, with unchanged Aβ load. Epifluorescence lifetime imaging of galectin-3 condensate composition would reveal whether both tau and Aβ/APP C99 fragments co-condense within the same galectin-3 puncta in vivo.\n\n### Target Gene/Protein\n**LGALS3** (galectin-3)\n\n---\n\n## Hypothesis 2: Steric Zipper Hexapeptide Interface Competition as Universal Cross-Seeding Inhibition Strategy\n\n### Mechanism\nCross-β steric zipper motifs from different disease proteins (τ^K18 VQIINK, α-syn^NAC VQVV, TDP-43 G336C MD fragment) occupy similar structural interfaces during amyloid nucleation, creating a competitive binding landscape at the growing fibril end. Short synthetic hexapeptides (e.g., Ac-IINVK-NH2, Ac-VQVVY-NH2) designed to occupy these shared zipper interfaces will act as universal cross-seeding inhibitors by outcompeting heterologous proteins for the nucleation core. This mechanism bypasses the need for protein-specific antibodies and targets the minimal structural unit (6-7 residue β-arch) required for cross-β propagation.\n\n### Key Evidence\nSoto and colleagues demonstrated that peptides designed to block steric zipper interfaces of Aβ reduce aggregation in vitro (Sanchez et al., 2019; PMID: **31340067**). Cross-seeding between α-synuclein and tau fragments shows sequence-dependent nucleation barriers that map to hexapeptide segments (Gu",
  "tokens_used": "696"
}